	US 11,865,191 B2
	Compositions and methods for enhanced fluorescence
Surbhi Desai, Rockford, IL (US); Marie Christine Nlend, Rockford, IL (US); Kyle Gee, Springfield, OR (US); Matthew Baker, Rockford, IL (US); Robert Aggeler, Eugene, OR (US); Scott Sweeney, Eugene, OR (US); Aleksey Rukavishnikov, Eugene, OR (US); and Shih-Jung Huang, Eugene, OR (US)
Assigned to Life Technologies Corporation, Carlsbad, CA (US); and Pierce Biotechnology, Inc., Rockford, IL (US)
Filed by Life Technologies Corporation, Carlsbad, CA (US); and Pierce Biotechnology, Inc., Rockford, IL (US)
Filed on May 22, 2020, as Appl. No. 16/882,271.
Application 16/882,271 is a continuation of application No. 15/693,772, filed on Sep. 1, 2017, abandoned.
Claims priority of provisional application 62/382,594, filed on Sep. 1, 2016.
Prior Publication US 2020/0330610 A1, Oct. 22, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 49/00 (2006.01); G01N 33/58 (2006.01); A61K 47/10 (2017.01); A61K 47/08 (2006.01); G01N 33/533 (2006.01); G01N 33/68 (2006.01); A61K 47/18 (2017.01)

CPC A61K 49/0015 (2013.01) [A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 49/0058 (2013.01); G01N 33/533 (2013.01); G01N 33/582 (2013.01); G01N 33/68 (2013.01)]

14 Claims

1. A composition, comprising a first conjugated antibody comprising two to ten fluorescent labels and two or more spacer molecules covalently attached to a first antibody, wherein the fluorescent labels and spacer molecules are not covalently attached to each other and wherein the composition exhibits increased fluorescence relative to a composition comprising a second conjugated antibody that is the same as and has a same degree of fluorescent labeling as the first conjugated antibody but that is lacking spacer molecules covalently attached to the second conjugated antibody, wherein the spacer molecules, which are covalently attached to the first antibody, are selected from sulfo-NHS-acetate, MS(PEG)₄, or NHS-Betaine.